COMPASS Pathways Announces Phase 3 Pivotal Program Design for COMP360 in Treatment Resistant Depression at Capital Markets Day

Posted: October 13, 2022 at 2:26 am

First ever phase 3 program of psilocybin therapy globally scheduled to begin in 2022 First ever phase 3 program of psilocybin therapy globally scheduled to begin in 2022

Read more here:
COMPASS Pathways Announces Phase 3 Pivotal Program Design for COMP360 in Treatment Resistant Depression at Capital Markets Day

Related Posts